A Kaposi's sarcoma-associated herpesvirus/human herpesvirus 8 ORF50 deletion mutant is defective for reactivation of latent virus and DNA replication.
Kaposi's sarcoma-associated herpesvirus (also called human herpesvirus type 8 [HHV8]) latently infects a number of cell types. Reactivation of latent virus can occur by treatment with the phorbol ester tetradecanoyl phorbol acetate (TPA) or with the transfection of plasmids expressing the lytic switch activator protein K-Rta, the gene product of ORF50. K-Rta expression is sufficient for the activation of the entire lytic cycle and the transactivation of viral genes necessary for DNA replication. In addition, recent evidence has suggested that K-Rta may participate directly in the initiation of lytic DNA synthesis. We have now generated a recombinant HHV8 bacterial artificial chromosome (BAC) with a large deletion within the ORF50 locus. This BAC, BAC36Delta50, failed to produce infectious virus upon treatment with TPA and was defective for DNA synthesis. Expression of K-Rta in trans in BAC36Delta50-containing cells was able to abolish both defects. Real-time PCR revealed that K-bZIP, ORF40/41, and K8.1 were not expressed when BAC36Delta50-containing cells were induced with TPA. However, the mRNA levels of ORF57 were over fivefold higher in TPA-treated BAC36Delta50-containing cells than those observed in similarly treated wild-type BAC-containing cells. In addition, immunohistochemical analysis showed that while the latency-associated nuclear antigen (LANA) was expressed in the mutant BAC-containing cells, ORF59 and K8.1 expression was not detected in TPA-induced BAC36Delta50-containing cells. These results showed that K-Rta is essential for lytic viral reactivation and transactivation of viral genes contributing to DNA replication.
Xu
Yiyang
Y
Department of Microbiology, School of Medicine, Howard Bldg., University of Nevada-Reno, Reno, NV 89557, USA.
AuCoin
David P
DP
Huete
Alicia Rodriguez
AR
Cei
Sylvia A
SA
Hanson
Lisa J
LJ
Pari
Gregory S
GS
D050976:Basic-Leucine Zipper Transcription Factors; D002352:Carrier Proteins / Q000235:genetics; D022202:Chromosomes, Artificial, Bacterial; D004261:DNA Replication; D017353:Gene Deletion; D015870:Gene Expression; D005816:Genetic Complementation Test; D006023:Glycoproteins / Q000235:genetics; D019288:Herpesvirus 8, Human / Q000235:genetics* / Q000502:physiology*; D012333:RNA, Messenger / Q000032:analysis; D012367:RNA, Viral / Q000032:analysis; D012097:Repressor Proteins; D020133:Reverse Transcriptase Polymerase Chain Reaction; D017384:Sequence Deletion; D015534:Trans-Activators / Q000235:genetics* / Q000502:physiology*; D014764:Viral Proteins / Q000235:genetics; D014775:Virus Activation; D014779:Virus Replication
D050976:Basic-Leucine Zipper Transcription Factors; D002352:Carrier Proteins; D006023:Glycoproteins; C118265:K8 protein, Human herpesvirus 8; C113454:K8.1 protein, Human herpesvirus 8; C116742:ORF 50 transactivator; D012333:RNA, Messenger; D012367:RNA, Viral; D012097:Repressor Proteins; D015534:Trans-Activators; D014764:Viral Proteins
J Virol. 2000 Apr;74(8):3586-97
10729134
J Virol. 1999 Nov;73(11):9348-61
10516043
J Virol. 2001 Feb;75(3):1487-506
11152521
J Virol. 2001 Aug;75(15):6786-99
11435557
J Virol. 2001 Aug;75(15):6894-900
11435569
Virology. 2001 Sep 15;288(1):119-28
11543664
Arch Virol. 2001 Jul;146(7):1415-26
11556717
J Virol. 2001 Dec;75(24):11961-73
11711586
J Gen Virol. 2002 Jan;83(Pt 1):189-93
11752716
Viral Immunol. 2001;14(4):311-7
11792061
Front Biosci. 2002 Mar 1;7:d726-30
11861213
J Biol Chem. 2002 Apr 26;277(17):14547-56
11832484
J Virol. 2002 May;76(10):5000-13
11967316
J Virol. 2002 Jun;76(12):6185-96
12021352
Mol Cells. 2002 Oct 31;14(2):185-91
12442889
J Virol. 2003 Jan;77(1):600-23
12477864
J Virol. 2003 Jan;77(2):1441-51
12502859
J Virol. 2003 Mar;77(6):3809-15
12610155
J Virol. 2003 May;77(10):5731-9
12719566
J Virol. 2003 Sep;77(17):9451-62
12915560
J Virol. 2003 Sep;77(17):9590-612
12915572
J Virol. 2003 Nov;77(21):11425-35
14557628
Virology. 2004 Jan 20;318(2):542-55
14972523
J Virol. 2004 Jun;78(12):6389-98
15163732
J Virol. 2004 Jun;78(12):6585-94
15163750
Proc Natl Acad Sci U S A. 2004 Jun 15;101(24):9073-8
15184661
J Gen Virol. 2004 Aug;85(Pt 8):2155-66
15269354
J Virol. 2004 Aug;78(16):8615-29
15280471
Nat Genet. 1994 Sep;8(1):33-41
7987390
J Virol. 1996 Dec;70(12):8340-7
8970953
J Clin Invest. 1997 Nov 15;100(10):2606-10
9366576
J Virol. 1998 Aug;72(8):6725-31
9658120
Proc Natl Acad Sci U S A. 1998 Sep 1;95(18):10866-71
9724796
J Virol. 1998 Dec;72(12):9526-34
9811685
J Virol. 1999 Oct;73(10):8320-9
10482582
J Virol. 2000 Jul;74(13):6207-12
10846108